Amgen: Sotorasib Responses Positive in Phase 2 Lung Cancer Study

 Amgen Inc. said Thursday its investigational drug, Sotorasib, has shown rapid, deep and durable response in a Phase 2 study.

The biotechnology company said 37.1% of patients with advanced non-small cell lung cancer responded to the treatment, with a median duration of response of ten months. Meanwhile, Median tumor shrinkage among all responders was 60%.

"We are extremely pleased that Sotorasib has successfully demonstrated rapid, deep and durable responses in this registrational Phase 2 study that was conducted in record time," Executive Vice President of Research and Development David Reese said.

https://www.marketscreener.com/quote/stock/AMGEN-INC-4847/news/Amgen-Sotorasib-Shows-Positive-Responses-in-Phase-Two-Study-32302821/